Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jörg U. Schmohl, Martin Felices, Felix Oh, Alexander J. Lenvik, Aaron M. Lebeau, Jayanth Panyam, Jeffrey S. Miller, Daniel A. Vallera
Cancer Res Treat. 2017;49(4):1140-1152. Published online 2017 Feb 20 DOI: https://doi.org/10.4143/crt.2016.491
Citations to this article as recorded by 
New immune cell engagers for cancer immunotherapy
Aurore Fenis, Olivier Demaria, Laurent Gauthier, Eric Vivier, Emilie Narni-Mancinelli
Nature Reviews Immunology.2024;[Epub] CrossRef
Natural killer cell therapies
Eric Vivier, Lucas Rebuffet, Emilie Narni-Mancinelli, Stéphanie Cornen, Rob Y. Igarashi, Valeria R. Fantin
Nature.2024; 626(8000): 727. CrossRef
Emerging Antibodies in Cancer Therapy
Yaping Sun, Jian Xu
Advanced NanoBiomed Research.2023;[Epub] CrossRef
Mapping the interplay between NK cells and HIV: therapeutic implications
Renee R Anderko, Robbie B Mailliard
Journal of Leukocyte Biology.2023; 113(2): 109. CrossRef
Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
Julia Harwardt, Stefania C. Carrara, Jan P. Bogen, Katrin Schoenfeld, Julius Grzeschik, Björn Hock, Harald Kolmar
Frontiers in Immunology.2023;[Epub] CrossRef
Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
Xinghui Xiao, Ying Cheng, Xiaodong Zheng, Yuhang Fang, Yu Zhang, Rui Sun, Zhigang Tian, Haoyu Sun
Frontiers in Immunology.2023;[Epub] CrossRef
NK cell defects: implication in acute myeloid leukemia
Selma Z. D’Silva, Meenakshi Singh, Andrea S. Pinto
Frontiers in Immunology.2023;[Epub] CrossRef
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Eunju Shin, Seong Ho Bak, Taeho Park, Jin Woo Kim, Suk-Ran Yoon, Haiyoung Jung, Ji-Yoon Noh
Frontiers in Immunology.2023;[Epub] CrossRef
Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy
Minchuan Zhang, Kong-Peng Lam, Shengli Xu
Frontiers in Immunology.2023;[Epub] CrossRef
Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
Tian Huan, Bugao Guan, Hongbo Li, Xiu Tu, Chi Zhang, Bin Tang
Human Vaccines & Immunotherapeutics.2023;[Epub] CrossRef
Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma
Titas Banerjee, Anusha Vallurupalli
Current Problems in Cancer.2022; 46(1): 100825. CrossRef
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
Xiaohu Zheng, Yaqi Wu, Jiacheng Bi, Yingying Huang, Ying Cheng, Yangyang Li, Yuwei Wu, Guoshuai Cao, Zhigang Tian
Cellular & Molecular Immunology.2022; 19(2): 192. CrossRef
Engineering interferons and interleukins for cancer immunotherapy
Patrick G. Holder, Shion A. Lim, Christine S. Huang, Preeti Sharma, Yavuz S. Dagdas, Beyza Bulutoglu, Jonathan T. Sockolosky
Advanced Drug Delivery Reviews.2022; 182: 114112. CrossRef
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Benjamin H. Goldenson, Pooja Hor, Dan S. Kaufman
Frontiers in Immunology.2022;[Epub] CrossRef
Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy
Wanze Zhang, Zhenghua Zhao, Fan Li
Molecular Immunology.2022; 144: 58. CrossRef
Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
Dain Moon, Nara Tae, Yunji Park, Seung-Woo Lee, Dae Hee Kim
Immune Network.2022;[Epub] CrossRef
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Nicholas A. Maskalenko, Dmitry Zhigarev, Kerry S. Campbell
Nature Reviews Drug Discovery.2022; 21(8): 559. CrossRef
Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
Mubin Tarannum, Rizwan Romee, Roman M. Shapiro
Frontiers in Immunology.2022;[Epub] CrossRef
Bispecific antibodies for immune cell retargeting against cancer
Rebecca P Chen, Kenta Shinoda, Pragya Rampuria, Fang Jin, Tin Bartholomew, Chunxia Zhao, Fan Yang, Javier Chaparro-Riggers
Expert Opinion on Biological Therapy.2022; 22(8): 965. CrossRef
The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications
Muhammad Sajid, Lianxin Liu, Cheng Sun
Frontiers in Immunology.2022;[Epub] CrossRef
Emerging Trends in Immunotherapy for Cancer
Alok K. Mishra, Amjad Ali, Shubham Dutta, Shahid Banday, Sunil K. Malonia
Diseases.2022; 10(3): 60. CrossRef
Drug-Tolerant Persister Cells in Cancer Therapy Resistance
Pavan Kumar Dhanyamraju, Todd D. Schell, Shantu Amin, Gavin P. Robertson
Cancer Research.2022; 82(14): 2503. CrossRef
Natural killer cells in antitumour adoptive cell immunotherapy
Tamara J. Laskowski, Alexander Biederstädt, Katayoun Rezvani
Nature Reviews Cancer.2022; 22(10): 557. CrossRef
TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
Michael F Kaminski, Laura Bendzick, Rachel Hopps, Marissa Kauffman, Behiye Kodal, Yvette Soignier, Peter Hinderlie, Joshua T Walker, Todd R Lenvik, Melissa A Geller, Jeffrey S Miller, Martin Felices
Journal for ImmunoTherapy of Cancer.2022; 10(9): e004725. CrossRef
The soldiers needed to be awakened: Tumor-infiltrating immune cells
Wang Yaping, Wang Zhe, Chu Zhuling, Li Ruolei, Fan Pengyu, Guo Lili, Ji Cheng, Zhang Bo, Liu Liuyin, Hou Guangdong, Wang Yaoling, Hou Niuniu, Ling Rui
Frontiers in Genetics.2022;[Epub] CrossRef
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
Xinyu Wu, Sandro Matosevic
Molecular Therapy - Oncolytics.2022; 27: 224. CrossRef
Multiplexed engineering and precision gene editing in cellular immunotherapy
Alexander Biederstädt, Gohar Shahwar Manzar, May Daher
Frontiers in Immunology.2022;[Epub] CrossRef
NK cells and ILCs in tumor immunotherapy
Simona Sivori, Daniela Pende, Linda Quatrini, Gabriella Pietra, Mariella Della Chiesa, Paola Vacca, Nicola Tumino, Francesca Moretta, Maria Cristina Mingari, Franco Locatelli, Lorenzo Moretta
Molecular Aspects of Medicine.2021; 80: 100870. CrossRef
Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy
Raynier Devillier, Anne-Sophie Chrétien, Thomas Pagliardini, Nassim Salem, Didier Blaise, Daniel Olive
Journal of Leukocyte Biology.2021; 109(6): 1071. CrossRef
Cancer stem cells and strategies for targeted drug delivery
Jin Cao, Shubhmita Bhatnagar, Jiawei Wang, Xueyong Qi, Swayam Prabha, Jayanth Panyam
Drug Delivery and Translational Research.2021; 11(5): 1779. CrossRef
The role of natural killer cell in gastrointestinal cancer: killer or helper
Feixue Wang, Jennie Ka Ching Lau, Jun Yu
Oncogene.2021; 40(4): 717. CrossRef
Next-Generation Immunotherapies to Improve Anticancer Immunity
Yaoyao Shi, Katarzyna Tomczak, June Li, Joshua K. Ochieng, Younghee Lee, Cara Haymaker
Frontiers in Pharmacology.2021;[Epub] CrossRef
Engineered Multifunctional Nano‐ and Biological Materials for Cancer Immunotherapy
Anthony Brouillard, Nilesh Deshpande, Ashish A. Kulkarni
Advanced Healthcare Materials.2021;[Epub] CrossRef
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
Cristina Capuano, Chiara Pighi, Simone Battella, Davide De Federicis, Ricciarda Galandrini, Gabriella Palmieri
Cancers.2021; 13(10): 2500. CrossRef
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments
Olivier Demaria, Laurent Gauthier, Guilhaume Debroas, Eric Vivier
European Journal of Immunology.2021; 51(8): 1934. CrossRef
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
Gihoon You, Jonghwa Won, Yangsoon Lee, Dain Moon, Yunji Park, Sang Hoon Lee, Seung-Woo Lee
Vaccines.2021; 9(7): 724. CrossRef
Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy
Shee Kwan Phung, Jeffrey S. Miller, Martin Felices
Molecular Diagnosis & Therapy.2021; 25(5): 577. CrossRef
Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors
Guangyu Lian, Thomas Shiu-Kwong Mak, Xueqing Yu, Hui-Yao Lan
International Journal of Molecular Sciences.2021; 23(1): 164. CrossRef
Targeting Natural Killer Cells for Tumor Immunotherapy
Cai Zhang, Yuan Hu, Chongdeng Shi
Frontiers in Immunology.2020;[Epub] CrossRef
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Aviad Ben-Shmuel, Guy Biber, Mira Barda-Saad
Frontiers in Immunology.2020;[Epub] CrossRef
Boosting Cytotoxic Antibodies against Cancer
Laurent Gauthier, Eric Vivier
Cell.2020; 180(5): 822. CrossRef
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
Margaux Lejeune, Murat Cem Köse, Elodie Duray, Hermann Einsele, Yves Beguin, Jo Caers
Frontiers in Immunology.2020;[Epub] CrossRef
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
Daniel A. Vallera, Soldano Ferrone, Behiye Kodal, Peter Hinderlie, Laura Bendzick, Brianna Ettestad, Caroline Hallstrom, Nicholas A. Zorko, Arpit Rao, Naomi Fujioka, Charles J. Ryan, Melissa A. Geller, Jeffrey S. Miller, Martin Felices
Cancers.2020; 12(9): 2659. CrossRef
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
Alexander Barrow, Marco Colonna
Cancers.2019; 11(1): 55. CrossRef
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Gaurav Nayyar, Yaya Chu, Mitchell S. Cairo
Frontiers in Oncology.2019;[Epub] CrossRef
Natural Killer Cells in Cancer Immunotherapy
Jeffrey S. Miller, Lewis L. Lanier
Annual Review of Cancer Biology.2019; 3(1): 77. CrossRef
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F. Kaminski, Sarah Cooley, Daniel J. Weisdorf, Daniel A. Vallera, Jeffrey S. Miller, Veronika Bachanova
Blood Advances.2019; 3(6): 897. CrossRef
Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses
Mathieu J.F. Crupi, John C. Bell, Ragunath Singaravelu
Stem Cells.2019; 37(6): 716. CrossRef
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier, Ariane Morel, Nadia Anceriz, Benjamin Rossi, Audrey Blanchard-Alvarez, Gwendoline Grondin, Sylvia Trichard, Cédric Cesari, Melody Sapet, Frédéric Bosco, Hélène Rispaud-Blanc, Franceline Guillot, Stéphanie Cornen, Alain Roussel, Béatrice
Cell.2019; 177(7): 1701. CrossRef
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Susanne Wingert, Thorsten Ross, Thomas Müller, Ute Schniegler-Mattox, Torsten Haneke, Erich Rajkovic, Joachim Koch, Martin Treder, Michael Tesar
mAbs.2019; 11(5): 899. CrossRef
T Cell–Activating Bispecific Antibodies in Cancer Therapy
Asaad Trabolsi, Artavazd Arumov, Jonathan H. Schatz
The Journal of Immunology.2019; 203(3): 585. CrossRef
Les anticorps etscaffoldbispécifiques, des médicaments innovants en oncologie impliquant le ciblage des cellules immunitaires
Patrick Chames, Thierry Wurch
médecine/sciences.2019; 35(12): 1072. CrossRef
Emerging trends in bispecific antibody and scaffold protein therapeutics
Petra Verdino, Shane Atwell, Stephen J Demarest
Current Opinion in Chemical Engineering.2018; 19: 107. CrossRef
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation
Sarah Cooley, Peter Parham, Jeffrey S. Miller
Blood.2018; 131(10): 1053. CrossRef
Bispecific antibodies in cancer immunotherapy
Eva Dahlén, Niina Veitonmäki, Per Norlén
Therapeutic Advances in Vaccines and Immunotherapy.2018; 6(1): 3. CrossRef
Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics
Martin Dalziel, Stephen A Beers, Mark S Cragg, Max Crispin
Glycobiology.2018; 28(9): 697. CrossRef
The role of CD133 in cancer: a concise review
Paige M. Glumac, Aaron M. LeBeau
Clinical and Translational Medicine.2018;[Epub] CrossRef
Advances and challenges in therapeutic monoclonal antibodies drug development
Mariana Lopes dos Santos, Wagner Quintilio, Tania Maria Manieri, Lilian Rumi Tsuruta, Ana Maria Moro
Brazilian Journal of Pharmaceutical Sciences.2018;[Epub] CrossRef
Redirecting T cells to hematological malignancies with bispecific antibodies
Mireya Paulina Velasquez, Challice L. Bonifant, Stephen Gottschalk
Blood.2018; 131(1): 30. CrossRef
Developmental and Functional Control of Natural Killer Cells by Cytokines
Yang Wu, Zhigang Tian, Haiming Wei
Frontiers in Immunology.2017;[Epub] CrossRef
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Zachary B. Davis, Daniel A. Vallera, Jeffrey S. Miller, Martin Felices
Seminars in Immunology.2017; 31: 64. CrossRef